{"id":"NCT02629861","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","briefTitle":"Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of Fremanezumab (TEV-48125) vs Placebo for the Preventive Treatment of Episodic Migraine","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-03-23","primaryCompletion":"2017-04-10","completion":"2017-04-10","firstPosted":"2015-12-14","resultsPosted":"2018-11-08","lastUpdate":"2021-11-09"},"enrollment":875,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Migraine"],"interventions":[{"type":"DRUG","name":"Fremanezumab","otherNames":["TEV-48125, anti-calcitonin gene-related peptide (anti-CGRP)"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Fremanezumab 675 mg/placebo/placebo","type":"EXPERIMENTAL"},{"label":"Fremanezumab 225/225/225 mg","type":"EXPERIMENTAL"}],"summary":"The study is being conducted to evaluate two doses of TEV-48125 in adult patients with episodic migraine","primaryOutcome":{"measure":"Change From Baseline in the Monthly Average Number of Migraine Days During the 12-Week Period After the First Dose of Study Drug","timeFrame":"Baseline (Days -28 to Day -1), Treatment (Days 1 - Week 12)","effectByArm":[{"arm":"Placebo","deltaMin":-2.7,"sd":null},{"arm":"Fremanezumab 675 mg/Placebo/Placebo","deltaMin":-4,"sd":null},{"arm":"Fremanezumab 225/225/225 mg","deltaMin":-4.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":8},"locations":{"siteCount":275,"countries":["United States","Canada","Czechia","Finland","Israel","Japan","Poland","Russia","Spain"]},"refs":{"pmids":["36038833","35331009","34819017","33413075","31752521","29800211"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":294},"commonTop":["Injection site pain","Injection site induration","Injection site erythema","Upper respiratory tract infection"]}}